Other News To Note
Friday, November 30, 2012
Epizyme Inc., of Cambridge, Mass., said preclinical data showed that treatment with EPZ-5676, an S-adenosyl methionine competitive DOT1L inhibitor, showed dose-dependent antitumor activity in a genetically defined rat model of MLL-rearranged leukemia, when given as a continuous infusion for 21 days, and resulted in complete tumor regression with the highest dose tested.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.